Entero Therapeutics’ novel algorithm for celiac disease featured in publication

Entero Therapeutics announced a publication in Clinical Gastroenterology and Hepatology, a journal of the American Gastroenterological Association that publishes diagnostic and therapeutic advances in clinical gastroenterology. The new approach in measuring clinically relevant histological endpoints presented in a peer-reviewed publication, led by Jack Syage, Chief Scientific Officer of Entero Therapeutics, recognized the need to advance beyond qualitative measures of histologic small intestinal health and to develop a more accurate and sensitive scale. The team created a composite score – VCIEL – for these two measures that helps overcome the individual variances to improve the overall accuracy of histological evaluation. The publication demonstrated the significant benefits of the VCIEL scale based on the results of four previous clinical trials. The significance of this achievement was highlighted in a special editorial feature by the journal, demonstrating the importance of this novel metric to CeD researchers.